Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
A phase 3 trial of Durvalumab, Bevacizumab in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.
Overview
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment is a phase 3 interventional study registered as NCT03847428 by AstraZeneca, with 908 participants enrolled, started 2019-04-29 and due to reach its primary completion in 2026-05-15. Interventions recorded: Durvalumab, Bevacizumab, Placebo. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat
Shares Durvalumab, Bevacizumab, AstraZeneca, Hepatocellular carcinoma.
- TrialA Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
Shares Durvalumab, Bevacizumab, AstraZeneca, Hepatocellular carcinoma.
- TrialDurvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
Shares Durvalumab, AstraZeneca, Hepatocellular carcinoma.
- TrialDurvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
Shares Durvalumab, AstraZeneca, Hepatocellular carcinoma.
- TrialA Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Shares Durvalumab, AstraZeneca.
- TrialStudy of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Shares Durvalumab, Bevacizumab, Hepatocellular carcinoma.
- TrialDurvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Shares Durvalumab, AstraZeneca, Hepatocellular carcinoma.
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Durvalumab, AstraZeneca.